SubsidieMeestersA unique commercially viable recombinant manufacturing platform for human fibrinogen (rhFib) & thrombin (rhThr
The RECOFIB platform produces customized, high-purity recombinant fibrinogen and thrombin from CHO cells, enabling innovative medical applications and reducing reliance on blood plasma.
Projectdetails
Introduction
We have developed the RECOFIB platform, a market-first recombinant production platform for human fibrinogen (rhFib) & thrombin (rhThr). Using Chinese Hamster Ovary Cells (CHO) expression technology & patented upstream purification processes, we are the first producer of fully intact & functional recombinant fibrinogen and active thrombin at commercially acceptable costs, ending reliance on blood plasma.
Breakthrough Discovery
Our RECOFIB platform can produce individual fibrinogen variants whose specific functional properties can now be fully harnessed—a breakthrough discovery.
Customized Product Development
From these individual variants, we can develop customized products for:
- Bioactive topical hemostats to stop excessive bleeding during surgery.
- Medical implant coating reducing antibiotic resistance of MRSA bacterial biofilms.
- Supply of rhFib variants & rhThr as OEM products.
Advantages of rhFib Variants
Additional benefits of our rhFib variants compared to plasma fibrinogen include:
- More stability
- 10,100X higher purity
- Improved safety profile
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 4.495.826 |
Tijdlijn
| Startdatum | 1-4-2022 |
| Einddatum | 31-12-2023 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- FIBRIANT BVpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
An innovative filtration system to improve the coagulation properties of plasma units to treat patients with massive bleedingPlasFree is developing ClearPlasma™, a filtration system that extracts plasminogen to improve haemorrhage treatment and reduce plasma unit requirements, aiming for clinical validation and global impact. | EIC Accelerator | € 1.279.184 | 2022 | Details |
Scalable and Eco-friendly BioproductionCore Biogenesis aims to become the European leader in plant-based biomanufacturing by 2025, using a novel process to significantly enhance yield and reduce costs for producing pharmaceutical proteins. | EIC Accelerator | € 1.153.390 | 2023 | Details |
Drug solution for bone fracture nonunionsGenera Research aims to develop OSTEOGROW-C, a novel biological drug using patients' blood to treat bone fracture nonunion, promising effective regeneration and reduced complications. | EIC Accelerator | € 2.499.999 | 2025 | Details |
The first effective and safe reversal agent to stop or prevent life-threatening bleeding in patients taking the emerging generation of anticoagulants.VarmX aims to develop VMX-C001, the first safe reversal agent for FXa-DOACs, to reduce life-threatening bleeding risks in anticoagulant patients, seeking €2.5M grant and €15M equity for scaling production. | EIC Accelerator | € 2.500.000 | 2022 | Details |
TowArd demoCRatization Of ev-BAsed TherapiesEVerZom aims to revolutionize EV manufacturing with a patented scalable process, targeting GMP compliance and commercial production to lead the European market in clinical applications. | EIC Accelerator | € 1.700.000 | 2022 | Details |
An innovative filtration system to improve the coagulation properties of plasma units to treat patients with massive bleeding
PlasFree is developing ClearPlasma™, a filtration system that extracts plasminogen to improve haemorrhage treatment and reduce plasma unit requirements, aiming for clinical validation and global impact.
Scalable and Eco-friendly Bioproduction
Core Biogenesis aims to become the European leader in plant-based biomanufacturing by 2025, using a novel process to significantly enhance yield and reduce costs for producing pharmaceutical proteins.
Drug solution for bone fracture nonunions
Genera Research aims to develop OSTEOGROW-C, a novel biological drug using patients' blood to treat bone fracture nonunion, promising effective regeneration and reduced complications.
The first effective and safe reversal agent to stop or prevent life-threatening bleeding in patients taking the emerging generation of anticoagulants.
VarmX aims to develop VMX-C001, the first safe reversal agent for FXa-DOACs, to reduce life-threatening bleeding risks in anticoagulant patients, seeking €2.5M grant and €15M equity for scaling production.
TowArd demoCRatization Of ev-BAsed Therapies
EVerZom aims to revolutionize EV manufacturing with a patented scalable process, targeting GMP compliance and commercial production to lead the European market in clinical applications.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Recombinant fibrinogen for extravascular support (EVS) after vein bypass graftingFibriant BV ontwikkelt een kosteneffectieve, recombinant fibrinogeenvariant voor extravasculaire steun bij bypass chirurgie om afsluiting van getransplanteerde aderen te verminderen. | Mkb-innovati... | € 315.100 | 2015 | Details |
STOPtheBLEED – Ontwikkeling van unieke combinatie van stollingsfactoren en gelatine particles om ernstige bloedingen veroorzaakt door trauma te stoppenSTOPtheBLEED ontwikkelt een innovatief hemostaseproduct voor het snel en effectief stoppen van ernstige bloedingen door trauma, gericht op gebruik door niet-medische hulpverleners. | Mkb-innovati... | € 335.944 | 2016 | Details |
Closing the European gap towards a large scale ex vivo platelet production built upon a silk-based scaffold bioreactorThe project aims to upscale ex vivo production of universal platelets using innovative technologies to meet rising demand and ensure compatibility for patients with transfusion reactions. | EIC Transition | € 1.798.152 | 2022 | Details |
ExCultureTechnologyExCulture ontwikkelt een alternatieve, niet-dierlijke heparineproductie via bioreactor fermentatie om tekorten en risico's van de huidige productie aan te pakken. | Mkb-innovati... | € 20.000 | 2023 | Details |
fibrinogen in bloed plasmaHet project onderzoekt de haalbaarheid van een eenvoudige point-of-care test voor het meten van functioneel fibrinogeen in bloedplasma. | Mkb-innovati... | € 20.000 | 2021 | Details |
Recombinant fibrinogen for extravascular support (EVS) after vein bypass grafting
Fibriant BV ontwikkelt een kosteneffectieve, recombinant fibrinogeenvariant voor extravasculaire steun bij bypass chirurgie om afsluiting van getransplanteerde aderen te verminderen.
STOPtheBLEED – Ontwikkeling van unieke combinatie van stollingsfactoren en gelatine particles om ernstige bloedingen veroorzaakt door trauma te stoppen
STOPtheBLEED ontwikkelt een innovatief hemostaseproduct voor het snel en effectief stoppen van ernstige bloedingen door trauma, gericht op gebruik door niet-medische hulpverleners.
Closing the European gap towards a large scale ex vivo platelet production built upon a silk-based scaffold bioreactor
The project aims to upscale ex vivo production of universal platelets using innovative technologies to meet rising demand and ensure compatibility for patients with transfusion reactions.
ExCultureTechnology
ExCulture ontwikkelt een alternatieve, niet-dierlijke heparineproductie via bioreactor fermentatie om tekorten en risico's van de huidige productie aan te pakken.
fibrinogen in bloed plasma
Het project onderzoekt de haalbaarheid van een eenvoudige point-of-care test voor het meten van functioneel fibrinogeen in bloedplasma.